Here's what thestreet.com had to say about IL-4 a month or two ago:
A new class, and one that is likely to perform the best,
attacks the most fundamental of the mediators, IL-4. IL-4 is
the first mediator to be released, and it starts the chain of
events that ultimately results in the symptoms of asthma.
Inhibiting or circumventing IL-4 will be critical. From this
perspective, I give a thumbs up to Glaxo Wellcome, Ligand
(LGND:Nasdaq) and Immunex (IMNX:Nasdaq). Of these
three, Immunex is the furthest along in the development
process, and its data, to be presented at the American
Association of Allergy, Asthma and Immunology
conference this March, will be most interesting. |
